



A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.

ENGOT-EN2-DGCG / EORTC-55102

n=678

**Endometrioid:
Stage I - G3; II**
**Non-endometrioid:
Stage I-II**

Chemotherapy
Carboplatin-Paclitaxel x 6
+ Brachytherapy

Observation
+ Brachytherapy

Supported by



Danish Cancer Society





Patient Population

5-year survival - FIGO



Stage		G1	G2	G3
Ia	1a	93	91	80
Ib	1a	92	93	82
Ic	1b	91	86	75
IIa	1b	90	84	68
IIb	2	81	77	65

Creasman et al., IJGO, 2007



ENGOT-EN2-DGCG / EORTC-55102

Group	PI	Country	No. of Institutions	Activated	Pts randomized
DGCG	Mirza	Denmark	6	6	42
NSGO	Lundgren	Sweden	4	4	22
		Finland	6	5	4
BGOG	Kridelka	Belgium	11	9	7
EORTC	Amant	Belgium	4	4	3
		Austria	1	1	1
		Germany	4	2	1
		Portugal	1	0	0
		Spain	4	4	8
		UK	11	9	10
		Netherlands	4	0	0
		Czech Rep.	1	1	1
MDACC	Soliman	US	1	1	1
MaNGO	Ferrero	Italy	6	1	0
MITO	Greggi	Italy	8	0	0
GEICO	Santabella	Spain	10	0	0
CEEGOG	Cibula	Czech Rep.	3-4	0	0
ISGO	Levy	Israel	6-7	0	0
NOGGO	Sehouli	Germany	5	0	0
Total			97	47	100